Back to search

Article

The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trials

2021-06-07

Abstract excerpt

<h4>Objectives</h4> The use of monoclonal antibody for COVID-19 showed conflicting results in prior studies and its efficacy remains unclear. We aimed to comprehensively determine the efficacy and safety profile of monoclonal antibodies in COVID-19 patients. <h4>Methods</h4> Sixteen RCTs were analyzed using RevMan 5.4 to measure the pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
856a361d-698c-55e0-8bc5-c0f413424f1a
DOI
10.1101/2021.06.04.21258343
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trialsDOI 10.1101/2021.06.04.21258343
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 TrialSemantic proximity
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesSemantic proximity
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 OutpatientsSemantic proximity
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of ConcernSemantic proximity
Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient settingSemantic proximity
Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity
Randomized controlled trials do not support efficacy of any of the tested doses of fluvoxamine in prevention of disease progression in adults with incipient non-severe COVID-19 disease: a case-study systematic review and meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.